MedTrace Logo

Effects of Epinephrine and Intravenous (I.V.) Needle on Cardiopulmonary Resuscitation (CPR) Outcome

NCT00121524 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 904

Last updated 2015-05-29

No results posted yet for this study

Summary

Intravenous epinephrine has been part of the guidelines for cardiopulmonary resuscitation since the start. It improves outcome in animal studies, but has never been investigated in a controlled study in humans. Epidemiologic data indicate that it is an independent negative predictor for survival. If this is true in a controlled randomized study, it could be due to effects of the drug itself or more likely due to reduced quality of chest compressions and ventilations due to the time spent on placing an I.V. needle and injecting drugs.

Conditions

  • Cardiac Arrest

Interventions

DRUG

Epinephrine

Epinephrine 1 mg is given iv. every 3 min during CPR

DEVICE

Intravenous needle

An intravenous needle in placed as soon as possible during CPR

DRUG

Atropine

Atropine 3 mg iv in initial systole

DRUG

Amiodarone

amiodarone 300 mg iv after repeated failed defibrillation attempts

Sponsors & Collaborators

  • Laerdal Medical

    collaborator INDUSTRY

  • Ullevaal University Hospital

    collaborator OTHER

  • Health Region East, Norway

    collaborator OTHER

  • Norwegian Air Ambulance Foundation

    collaborator OTHER

  • University of Oslo

    collaborator OTHER

  • Petter Andreas Steen

    lead OTHER

Principal Investigators

  • Lars Wik, MD, PhD · Ullevaal University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2008-05-31
Completion
2008-06-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00121524 on ClinicalTrials.gov